News >

Axi-Cel Plus Atezolizumab Active, Safe in DLBCL

Jason M. Broderick @jasoncology
Published: Friday, Jan 12, 2018

Frederick L. Locke, MD

Frederick L. Locke, MD
The combination of the anti‑CD19 chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) and the PD-L1 inhibitor atezolizumab (Tecentriq) was highly active with a manageable safety profile in patients with refractory diffuse large B-cell lymphoma (DLBCL) enrolled in the phase I/II ZUMA-6 trial.1

Axi-cel–related AEs occurred in all 9 patients and 4 patients experienced atezolizumab-related AEs. Overall, 8 patients experienced grade 3/4 AEs. There were 3 grade 3 and 4 grade 4 AEs related to axi-cel, and 1 grade 4 AE related to atezolizumab. 

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication